Novo Nordisk (NVO) · Pharmaceuticals
Novo Nordisk Q2 2026 earnings: summary, key numbers & outlook
Results filed 4 Aug 2026 · Quarter ended 30 Jun 2026
Press release ↗Investor relations ↗
Summaries and transcripts are machine-generated and can contain errors.
In brief
Wegovy pill became the strongest-ever US GLP-1 volume launch, passing 265,000 weekly prescriptions and starting to roll out abroad, as Novo Nordisk raised its 2026 outlook.
Novo Nordisk's oral obesity drug Wegovy pill, launched in the US on 5 January, has now passed 5 million prescriptions, and weekly prescriptions topped 265,000 in mid-July. It is sold through over 70,000 pharmacies, nine telehealth organisations and a new subscription option. Wegovy HD (7.2 mg) launched in the US in April. Outside the US, Wegovy pill launched in the UAE and UK, and both it and the 7.2 mg single-dose pen won EU approval in July.
Management is steering toward broader access and more markets: Medicare Part D coverage through the Bridge pilot, a wider Wegovy pill rollout, and more than 30 markets for the 7.2 mg pen. The tension is price and competition. Realised prices are falling, injectable Wegovy sales dropped in the US, and the CEO says the company is not positioned for large acquisitions while Eli Lilly leads the market. The ZEUS trial for ziltivekimab also missed its primary endpoint.
No call transcript for this quarter, so this summary also draws on: Pharmaceutical Technology ↗, Indian Pharma Post ↗.
Key numbers
- Net sales · GAAP
- 78.5B
- Operating profit · GAAP
- 27.1B
- Adjusted operating profit · non-GAAP
- 33.4B
- Net profit · GAAP
- 21.0B
- Diluted EPS per ADR (DKK) · GAAP
- 4.75
- Adjusted diluted EPS per ADR (DKK) · non-GAAP
- 6.18
- Gross margin · GAAP
- 78.2%
- Operating margin · GAAP
- 34.5%
up 3% at CER
down 16% at CER
up 11% at CER
down 21% in DKK
down 20% in DKK
up 5% in DKK
| Segment or metric | Value | Change |
|---|---|---|
| Total Obesity care (adjusted) | 23.2B | up 16% at CER |
| Wegovy injectable | 19.5B | up 1% at CER |
| Wegovy pill | 3.2B | |
| Ozempic | 31.4B | up 5% at CER |
| Ozempic pill / Rybelsus | 5.2B | down 4% at CER |
| Rare disease | 4.9B | up 6% at CER |
| US Operations | 40.9B | up 4% at CER (adjusted) |
| International Operations | 37.6B | up 10% at CER |
Where each number comes from
- Net sales: “Net sales | 78,488 | 2% | 3% | 175,311 | 13% | 18% Operating profit | 27,061 | (19 | %) | (16 | %) | 86,679”
- Operating profit: “Operating profit | 27,061 | (19 | %) | (16 | %) | 86,679 | 20% | 27% Adjusted net sales1 | 78,488”
- Adjusted operating profit: “Adjusted operating profit1,2 | 33,389 | 8% | 11% | 66,247 | (5 | %) | 2% CER: Constant exchange rates”
- Net profit: “Net profit | 20,989 | (21%) | N/A | 69,546 | 25% | N/A Adjusted net profit1 | 27,421 | 5% | N/A”
- Diluted EPS per ADR (DKK): “Diluted earnings per share / ADR (in DKK) | 4.75 | (20%) | N/A | 15.66 | 25% | N/A Adjusted diluted earnings per share/ADR”
- Adjusted diluted EPS per ADR (DKK): “Adjusted diluted earnings per share/ADR (in DKK)1 | 6.18 | 5% | N/A | 12.81 | 1% | N/A 1) See appendix 7”
- Gross margin: “Gross margin | 78.2% | 82.5% Operating profit (EBIT) | 27,061 | (19%) | (16 | %) | 86,679 | 20% | 27% Operating margin | 34.5%”
- Operating margin: “Operating margin | 34.5% | 49.4% Adjusted gross profit1 | 61,388 | 0% | 2% | 117,853 | (7%) | (2 | %) Adjusted gross margin”
- Total Obesity care (adjusted): “Total Obesity care | 23,152 | 15% | 16% | 44,064 | 14% | 19% Total Diabetes care | 50,429 | 2% | 3%”
- Wegovy injectable: “Wegovy® injectable | 19,484 | 1% | 1% | 37,719 | 3% | 7% Wegovy® pill | 3,218 | N/A | N/A”
- Wegovy pill: “Wegovy® pill | 3,218 | N/A | N/A | 5,474 | N/A | N/A Ozempic® | 31,375 | 3% | 5%”
- Ozempic: “Ozempic® | 31,375 | 3% | 5% | 59,200 | (6%) | (2%) Ozempic®pill / Rybelsus® | 5,228 | (7%) | (4%)”
- Ozempic pill / Rybelsus: “Ozempic®pill / Rybelsus® | 5,228 | (7%) | (4%) | 9,800 | (13%) | (9%) Gross profit | 61,388”
- Rare disease: “Rare disease total | 4,907 | 2% | 6% | 9,122 | (3%) | 2% Adjusted sales for key brands”
- US Operations: “US Operations | 40,869 | 1% | 4% | 76,254 | (10 | %) | (4 | %) International Operations | 37,619 | 11% | 10%”
- International Operations: “International Operations | 37,619 | 11% | 10% | 72,297 | 7% | 8% - EUCAN | 19,206 | 17% | 17%”
Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.
Outlook
| Metric | Period | Outlook |
|---|---|---|
| Adjusted sales growth at CER | 2026 | 0% to -6% |
| Adjusted operating profit growth at CER | 2026 | 0% to -6% |
Key takeaways
Wegovy pill is the strongest US GLP-1 launch
Weekly prescriptions exceeded 265,000 for the week ending 17 July, with more than 5 million since launch, driven by GLP-1-naïve patients and self-pay. Formulary access is on par with injectable Wegovy.
Direct-to-patient channels and subscriptions are expanding
Novo Nordisk is adding a subscription option for Wegovy and Wegovy pill (3, 6 or 12 months) through Ro, WeightWatchers and LifeMD, with Hims & Hers and Sesame expected. Self-pay pricing of USD 149–299 per month by dose makes cash-pay a core route to patients.
Medicare Bridge opens a new US obesity channel
Medicare Part D obesity coverage began 1 July through the Bridge pilot, covering a majority of beneficiaries, with encouraging early uptake. It stems from the November 2025 agreement with the US Administration, which also covers Medicaid and self-pay.
International obesity growth is led by Wegovy volume
International Operations obesity care sales rose 37% at CER on higher Wegovy volume, with EUCAN up 52%, though lower realised prices, especially in China, offset part of it. Wegovy pill launched in the UAE and UK, with more markets planned.
Higher-dose and pipeline moves mixed
Wegovy HD launched in the US in April and is on the three largest PBMs' formularies, while the 7.2 mg pen is approved in the EU. Against that, ziltivekimab's ZEUS trial missed its primary endpoint and DKK 6.3 billion of pipeline impairments included monlunabant.
Questions
How is the Wegovy pill performing in the US?
Weekly prescriptions exceeded 265,000 for the week ending 17 July, and total prescriptions since the 5 January launch passed 5 million. Novo Nordisk calls it the strongest-ever GLP-1 volume launch in the US.
Where is Wegovy pill launching outside the US?
It launched in the UAE in June and the UK in July, with encouraging early uptake, and received EMA approval in July. More launches in select markets are planned in coming quarters.
What is Novo Nordisk doing to widen US access to obesity drugs?
It started Medicare Part D obesity coverage via the Bridge pilot on 1 July, expanded telehealth partnerships and a subscription programme, and secured Wegovy HD on the three largest PBMs' formularies. CVS Caremark will add other weight loss medications to its largest commercial template formularies from 1 October 2026.
How is Novo Nordisk positioned against Eli Lilly?
Novo Nordisk says Wegovy remains the market leader among branded US obesity medications by new patient starts. Press coverage describes Novo as relying on the pill to bridge the gap to Eli Lilly, the dominant drugmaker in obesity and type 2 diabetes.
Is Novo Nordisk planning large acquisitions?
The CEO said the company is not currently in a position to pursue large-scale M&A, with bolt-ons favoured over transformative deals. He also said that no company has a monopoly on good ideas.
Documents
SEC filing